A novel chiral oxazoline copper(ii)-based complex inhibits ovarian cancer growthin vitroandin vivoby regulating VEGF/VEGFR2 downstream signaling pathways and apoptosis factors

Q: How does OCRA curate its research paper database?

OCRA indexes peer-reviewed papers from PubMed and CrossRef, enriched with MeSH terms, author profiles, and citation metrics. Papers are categorized by cancer type, research method, and clinical relevance.

Q: Can I search papers by MeSH term or author?

Yes. Use the search bar to filter papers by MeSH term, author name, journal, keyword, or cancer type. Each paper includes linked MeSH terms and author profiles for further exploration.

Q: How current is the paper database?

The database is updated regularly through automated ingestion from PubMed and CrossRef. Most papers appear within days of their PubMed indexing date.

Xiu-Ying Qin

doi:10.1039/d3dt01648j

A novel chiral oxazoline copper(ii)-based complex inhibits ovarian cancer growthin vitroandin vivoby regulating VEGF/VEGFR2 downstream signaling pathways and apoptosis factors

Xiu-Ying Qin · 2023-08-22

9Citations

An oxazoline-coordinated copper complex regulates the VEGF/VEGFR2 signaling pathway and apoptosis-related factors to resist ovarian cancerin vivoandin vitro.

Links

DOI PubMed

Journal

Dalton Transactions

TL;DR

Cu-A significantly inhibits ovarian tumor growth in vivo by inhibiting tumor cells from inducing vascular endothelial cells to form their own vasculature and by up-regulating the expression of the pro-apoptotic proteins Caspase-9 and Bax to induce apoptosis of tumor cells.

AI-generated by Semantic Scholar

A novel chiral oxazoline copper(ii)-based complex inhibits ovarian cancer growthin vitroandin vivoby regulating VEGF/VEGFR2 downstream signaling pathways and apoptosis factors

Links

Journal

TL;DR

Institutions

Authors

Funding